FDA Critical Path Initiatives: Opportunities for Generic Drug Development
FDA Critical Path Initiatives: Opportunities for Generic Drug Development
FDA's critical path initiative documents have focused on the challenges involved in the development of new drugs. Some of the focus areas identified apply equally to the production of generic drugs. However, there are scientific challenges unique to the development of generic drugs as well. In May 2007, FDA released …